Transcriptome analysis of untreated multiple myeloma cells and multiple myeloma cells treated with T6, F2, I3C and DIM
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA782497 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR17000693_1.fastq.gz | Fastqsanger.gz | |||
| SRR17000693_2.fastq.gz | Fastqsanger.gz | |||
| SRR17000694_1.fastq.gz | Fastqsanger.gz | |||
| SRR17000694_2.fastq.gz | Fastqsanger.gz | |||
| SRR17000695_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 10 |
Similar Datasets
Project description:Transcriptome sequencing was used to analyze the changes of related signaling pathways and gene expression in multiple myeloma cells after the addition of T6, F2, I3C and DIM.
2023-10-04 | GSE189309 | GEO
Project description:Our laboratory observed that indoles (I3C and DIM) suppressed the development of delayed type hypersensitivity (DTH) in mice. Also, we observed differential regulation of regulatory T cells (Tregs) and Th17 cells in mice treated with I3C or DIM. The aim of this experiment was, therefore, to understand the role of I3C or DIM in the regulation of microRNAs (miRs) in immune cells and generation of Tregs and Th17 cells. We also used FICZ, an aryl hydrocarbon receptor (AhR) ligand to understand the role of various ligands in the regulation of Tregs and Th17 cells. To this end, we used draining (inguinal) lymph nodes (LNs) of mice (C57BL/6) with DTH and treated with Vehicle (corn oil, VEH) or I3C or DIM or FICZ. In brief, total RNA including miRs from inguinal LNs were isolated using miRNeasy kit and the protocol of the company was followed (QIAGEN, Valencia, CA). Next, miR arrays were performed at Johns Hopkins University Microarray and Sequencing Core facility using platform.
2019-01-02 | E-MTAB-4076 | biostudies-arrayexpress
Project description:The multiple myeloma (MM) data set (endpoints F, G, H, and I) was contributed by the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (UAMS, Little Rock, AR, USA). Gene expression profiling of highly purified bone marrow plasma cells was performed in newly diagnosed patients with MM. The training set consisted of 340 cases enrolled on total therapy 2 (TT2) and the validation set comprised 214 patients enrolled in total therapy 3 (TT3). Plasma cells were enriched by anti-CD138 immunomagnetic bead selection of mononuclear cell fractions of bone marrow aspirates in a central laboratory. All samples applied to the microarray contained more than 85% plasma cells as determined by 2-color flow cytometry (CD38+ and CD45-/dim) performed after selection. Dichotomized overall survival (OS) and eventfree survival (EFS) were determined based on a two-year milestone cutoff. A gene expression model of high-risk multiple myeloma was developed and validated by the data provider and later on validated in three additional independent data sets.
2010-09-11 | GSE24080 | GEO
Project description:The paper describes a model of multiple myeloma.
Created by COPASI 4.26 (Build 213)
This model is described in the article:
A mathematical model of cell equilibrium and joint cell formation in multiple myeloma
M.A. Koenders, R. Saso
Journal of Theoretical Biology 390 (2016) 73–79
Abstract:
In Multiple Myeloma Bone Disease healthy bone remodelling is affected by tumour cells by means of paracrine cytokinetic signalling in such a way that osteoclast formation is enhanced and the growth of osteoblast cells inhibited. The participating cytokines are described in the literature. Osteoclast-induced myeloma cell growth is also reported. Based on existing mathematical models for healthy bone remo- delling a three-way equilibrium model is presented for osteoclasts, osteoblasts and myeloma cell populations to describe the progress of the illness in a scenario in which there is a secular increase in the cytokinetic interactive effectiveness of paracrine processes. The equilibrium state for the system is obtained. The paracrine interactive effectiveness is explored by parameter variation and the stable region in the parameter space is identified. Then recently-discovered joint myeloma–osteoclast cells are added to the model to describe the populations inside lytic lesions. It transpires that their presence expands the available parameter space for stable equilibrium, thus permitting a detrimental, larger population of osteoclasts and myeloma cells. A possible relapse mechanism for the illness is explored by letting joint cells dissociate. The mathematics then permits the evaluation of the evolution of the cell populations as a function of time during relapse.
To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models .
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide.
Please refer to CC0 Public Domain Dedication for more information.
2024-09-02 | BIOMD0000000804 | BioModels
Project description:<h4><strong>BACKGROUND:</strong> Multiple myeloma is characterized by clonal proliferation of malignant plasma cells in the bone marrow that produce monoclonal immunoglobulins. N-glycosylation changes of these monoclonal immunoglobulins have been reported in multiple myeloma, but previous studies only detected limited serum N-glycan features.</h4><h4><strong>METHODS:</strong> Here, a more detailed study of the human serum N-glycome of 91 multiple myeloma patients and 51 controls was performed. We additionally analyzed sequential samples from patients (n = 7) which were obtained at different time points during disease development as well as 16 paired blood serum and bone marrow plasma samples. N-glycans were enzymatically released and measured by mass spectrometry after linkage specific derivatization of sialic acids.</h4><h4><strong>RESULTS:</strong> A decrease in both α2,3- and α2,6-sialylation, galactosylation and an increase in fucosylation within complex-type N-glycans were found in multiple myeloma patients compared to controls, as well as a decrease in difucosylation of diantennary glycans. The observed glycosylation changes were present in all ISS stages, including the 'low-risk' ISS I. In individual patients, difucosylation of diantennary glycans decreased with development of the disease. Protein N-glycosylation features from blood and bone marrow showed strong correlation. Moreover, associations of monoclonal immunoglobulin (M-protein) and albumin levels with glycan traits were discovered in multiple myeloma patients.</h4><h4><strong>CONCLUSIONS & GENERAL SIGNIFICANCE: </strong>In conclusion, serum protein N-glycosylation analysis could successfully distinguish multiple myeloma from healthy controls. Further studies are needed to assess the potential roles of glycan trait changes and the associations of glycans with clinical parameters in multiple myeloma early detection and prognosis.</h4>
2022-04-27 | MTBLS676 | MetaboLights
Project description:Gene Expression profiling of 170 newly diagnosed Multiple Myeloma patients Gene Expression profiling of Multiple Myeloma Cells from Healthy donors and Multiple myeloma patients were profiled using Affymetrix Exon-1.0 ST microarrays
2012-09-10 | E-GEOD-39754 | biostudies-arrayexpress
Project description:Human Multiple Myeloma ATAC. This series contains the ATAC-seq data for Human Multiple Myeloma patients.
| PRJEB28803 | ENA
Project description:CELF2 regulation in multiple myeloma
| PRJNA1279000 | ENA